Google
GALT — GALECTIN THERAPEUTICS INC (Healthcare >> Biotechnology)
GALT FAQ
What is GALT's ROE?
GALECTIN THERAPEUTICS INC reports a Return on Equity (ROE) of 20.16%.
What is GALT's dividend yield?
GALECTIN THERAPEUTICS INC offers a dividend yield of 0.00%.
What is GALT's Deepscope Quality Score?
Deepscope rates GALT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GALT?
Deepscope's AI Timing Score for GALT is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GALT belong to?
GALECTIN THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.41
Price
0.01
(0.42%)
Day Change
|
|
|---|
GALT, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.41 |
| PBV / Sector |
-1.21 / 4.71
|
| Earning Per Share | -0.40 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.79 M
GREAT
|
| Average 1W Daily Value |
0.49 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:44:04 |
| Symbol | GALT |
| Name | GALECTIN THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.86 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 158.06 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071
Phone: 678 620 3186
Website: https://galectintherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
